Other

Imugene Ltd.

Bio Life Science Forschungs- Und Entwicklungsges.m.b.h.

Christoph Zielinski

Erika Jensen-Jarolim

Otto Scheiner

Heimo Breiteneder

Ursula Wiedermann

Hubert Pehamberger

Hubert Penamberger

Joshua Tobias

Nicholas Ede

Prof Dr Ursula-Wiedermann Ursula-Wiedermann

Otto Schreiner

Disclosed herein is a vaccine composition for raising a humoral response to PD1, and uses thereof, for treating a cancer characterised by an involvement of PD1, wherein the vaccine composition comprises an effective amount of an immunogen that induces an antibody response in which the antibody binds to a B cell epitope of PD1.

Vaccine composition and uses thereof

The present invention relates to peptides of the extracellular domain of a HER-2/neu protein, conjugates comprising said peptides linked to an immunogenic carrier, compositions thereof, nucleic acid molecules, vectors and transformed or transfected host cells comprising said nucleic acid molecules encoding said peptides or conjugates, and methods for producing the disclosed peptides, conjugates and compositions. The present invention also relates to diagnostic methods of detecting cancerous conditions associated with HER-2/neu or monitoring the effectiveness of treatment against cancerous conditions associated with HER-2/neu. The present invention also relates to methods of eliciting or enhancing an immune response to HER-2/neu in a subject in need thereof.

Vaccine against cancer diseases that are associated with the her-2/neu oncogene

The present invention provides a method for producing a vaccine against cancerous disease, and the vaccine itself. This method involves first using one or more antibodies that are specifically effective against one or more antigens specially expressed by the tumor cells to select one or more mimotopes of said antigens from a phage peptide library. To obtain the vaccine, said mimotopes are conjugated to a macromolecular carrier singly or multiply in the form of their mono-, di-, tri- or oligomers. When administered, the inventively produced vaccine leads to a humoral immune response and thus to the formation of an active immunity as a consequence of vaccination.

Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells

Growing community of inventors

Vienna, Austria

Christoph Zielinski